Choose Your Location
|
![]() |
WOODCLIFF LAKE, N.J. (Map) -
Ms. Schwalm brings to Eisai Inc. a strong track record of building
high-performing organizations that drive global growth and nearly 25 years of
senior healthcare experience in the fields of pharmaceuticals, biotechnology
and medical devices. She will report to
"Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the U.S. as a top-20 pharmaceutical company," said Mr. Coats. "Ms. Schwalm has an extensive background in oncology, neurology, critical care and gastroenterology, areas of therapeutic focus for Eisai. She will be invaluable to our future growth, as we continue to advance our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."
Ms. Schwalm joins Eisai from Amgen, Inc., where over the course of her
five-year tenure she rose to Vice President and General Manager of the U.S.
Oncology Business Unit, a group with annual revenues exceeding
Prior to Amgen, Inc., Ms. Schwalm grew her pharmaceutical career over an
18-year period within Johnson & Johnson (J&J), holding positions of increasing
responsibility at various J&J companies. During this time, Ms. Schwalm gained
experience in oncology commercialization and also developed sales and
marketing expertise in critical care, neurology/analgesia and
gastroenterology. In her last assignment at J&J, she spent several years in
the
Ms. Schwalm holds a Bachelor of Science degree in nursing from the
About Eisai Corporation of
Eisai Corporation of
SOURCE Eisai Corporation of
|
|


